Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 10/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043738 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043963 | 0.95 | ABL1 (0.53) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043862 | 0.93 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043968 | 0.91 | ABL1 (0.48) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL854802 | 0.90 | RAB9A (0.55) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043966 | 0.90 | ABL1 (0.47) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043867 | 0.90 | ABL1 (0.47) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043964 | 0.89 | ABL1 (0.47) | KDM4EALDH1A1HPGDHSD17B10ABL1 | |
| SCHEMBL10043832 | 0.88 | NPC1 (0.52) | KDM4EALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL10043871 | 0.88 | ABL1 (0.46) | KDM4EALDH1A1HPGDHSD17B10ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | KDM4E 1572/4885ALDH1A1 4274/4885HPGD 4653/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | KDM4E 1572/4885ALDH1A1 4274/4885HPGD 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.